<p>Cuprina Holdings (Cayman) Ltd. has entered into a joint venture agreement with Singapore-based Aiodine Laboratory Pte Ltd. to develop, test, and market a novel iodine-based disinfectant solution for wound care and antiseptic applications. Under the agreement, Cuprina will oversee global sales, marketing, and distribution, while Aiodine Laboratory will provide proprietary iodine technology and technical expertise. The initial focus will be on wound care formulations, disinfectants, and daily antiseptics, with additional opportunities in personal care, oral hygiene, and veterinary applications under evaluation. Clinical studies for regulatory approval are planned to begin in 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cuprina Holdings (Cayman) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9577846-en) on November 18, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

CUPR

<p>Cuprina Holdings (Cayman) Ltd. has formed a joint venture with Aiodine Laboratory Pte Ltd. to develop, test, and market an iodine-based disinfectant solution for wound care and antiseptic applications. Cuprina will handle global sales and distribution, while Aiodine provides iodine technology. Clinical studies for regulatory approval are planned for 2026.</p>

Cuprina Holdings Forms Joint Venture with Aiodine Laboratory to Develop Iodine-Based Wound Care Solution